Recent Company News

• 08:45 PM ET Oct 20, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 05:38 PM ET Dec 01, 2025
  

  Immutep to present new data from AIPAC-003 Phase II efti trial in female participants with MBC at the 2025 SABCS (A$0.30, 0.00)

• 04:40 PM ET Nov 12, 2025
  

  Immutep positive data from the EFTISARC-NEO trial presented at Connective Tissue Oncology Society Annual meeting (A$0.27, 0.00)

• 05:30 PM ET Nov 02, 2025
  

  Immutep reports receipt of €2.6M (~ A$4.6M) R&D tax incentive payment from French government (A$0.28, 0.00)

• 05:27 PM ET Oct 28, 2025
  

  Immutep reports Q1 net cash used in operating activities (A$19.0M) - Appendix 4C (A$0.29, 0.00)

• 05:31 PM ET Oct 19, 2025
  

  Immutep presents two poster presentations focusing on changing treatment paradigm in first line non-small cell lung cancer at ESMO (A$0.31, 0.00)